In The Claims

Please cancel claims 3-6, 8, 16, 20, and 21 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a continuation application.

Please amend claims 1, 2, 7, 9-13, 17, 19 22-24 and 27 as follows:

--1. A method for treating or preventing stroke in a human subject susceptible to intracranial hemorrhaging, comprising administering to the human subject an effective amount of a CD39 polypeptide comprising consecutive amino acids the sequence of which is set forth in SEQ ID [NO. 1] NO:1 or an active polypeptide fragment thereof so as to inhibit adenosine diphosphate-mediated platelet aggregation by increasing adenosine diphosphate catabolism without increasing incidence of intracerebral hemorrhage in the human subject.--

--2. (Amended) The method of claim 1, wherein the active polypeptide fragment of CD39 polypeptide is a mutated or a truncated form of the CD39 polypeptide.--

--7. (Amended) The method of claim 1, wherein an active fragment of the CD39 polypeptide comprises consecutive amino acids the sequence of which is identical to the sequence of amino acid residues 20-80 of SEQ ID NO: 1.--

--9. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the active

fragment thereof occurs at the onset of stroke in the subject.--

--10. (Amended) The method of claim 1 wherein the administration of the CD39 polypeptide or the active fragment thereof is prior to stroke onset in the subject.--

--11. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the active fragment thereof occurs after the onset of stroke in the subject.--

--12. (Amended) The method of claim 1, wherein the CD39 polypeptide or the active fragment thereof is administered in a dosage of 1-20 mg/kg of the subject's body weight.--

--13. (Amended) The method of claim 1, wherein the CD39 polypeptide or the active fragment thereof is administered in a dosage of 4-8 mg/kg of the subject's body weight.--

---

--17. (4X Amended) A method for testing a compound comprising:

(a) administering a compound which increases ADP catabolism to an animal, which is a model for the thrombotic or ischemic disorder, before, concurrently with or after step (b);

(b) inducing the thrombotic or ischemic disorder in the animal;

(c) measuring the stroke outcome and the incidence of intracerebral hemorrhage in the animal;

(d) measuring platelet or fibrin deposition or both in ischemic tissue in the animal; and

(e) comparing the stroke outcome and the platelet and/or fibrin deposition in the presence of the compound or in the absence of the compound, so as to determine whether the compound is capable of treating or preventing the thrombotic or ischemic disorder in the subject.--

--19. (Amended) The method of claim 17, wherein the stroke outcome is measured as platelet deposition, bleeding time and infarction volume.--

--22. (Amended) The method of claim 17, wherein the administration of the compound is before step (b).--

--23. (Amended) The method of claim 17, wherein the administration of the compound is concurrent with step (b).--

--24. (Amended) The method of claim 17, wherein the administration of the compound is after step (b).--

--27. (Amended) A method for treating or preventing stroke in a human subject susceptible to intracranial hemorrhaging, comprising administering to the human subject an effective amount of a deletion mutant, substitution mutant, or insertion mutant of the CD39

polypeptide, which CD39 polypeptide comprises consecutive amino acids having the sequence shown in SEQ ID NO:1, so as to inhibit adenosine diphosphate-mediated platelet aggregation by increasing adenosine diphosphate catabolism without increasing incidence of intracerebral hemorrhage in the human subject. --

Please add new claims 28-38:

- stroke in the subject.--

--34. (New) The method of claim 28, wherein the CD39 polypeptide or the active fragment thereof is administered in a dosage of 1-20 mg/kg of the subject's body weight.--

--35. (New) The method of claim 28, wherein the CD39 polypeptide or the active fragment thereof is administered in a dosage of 4-8 mg/kg of the subject's body weight.--

--36. (New) The method of claim 1, wherein the administration of the CD39 polypeptide or the active polypeptide fragment thereof is effected prior to stroke onset in the human subject.--

--37. (New) The method of claim 1, wherein the administration of the CD39 polypeptide or the active polypeptide fragment thereof is effected at the onset of stroke in the human subject.--

--38. (New) The method of claim 1, wherein the administration of the CD39 polypeptide or the active polypeptide